Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.5% in the first quarter, Holdings Channel reports. The fund owned 156,456 shares of the medical equipment provider’s stock after purchasing an additional 6,712 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Intuitive Surgical were worth $62,440,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Provence Wealth Management Group acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $276,000. Portside Wealth Group LLC raised its stake in shares of Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after buying an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after buying an additional 3,054 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Intuitive Surgical by 5.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock worth $64,531,000 after buying an additional 9,869 shares in the last quarter. Finally, HCR Wealth Advisors raised its stake in shares of Intuitive Surgical by 26.3% during the 4th quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after buying an additional 217 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 5,318 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the sale, the executive vice president now owns 298 shares in the company, valued at $110,456.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. Insiders have sold 17,956 shares of company stock worth $6,927,011 over the last quarter. 0.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ISRG. Stifel Nicolaus increased their target price on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. BTIG Research increased their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Piper Sandler increased their target price on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Citigroup raised their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, Robert W. Baird dropped their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $403.67.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $445.11 on Friday. The stock has a fifty day moving average of $400.81 and a two-hundred day moving average of $381.34. The company has a market capitalization of $157.88 billion, a price-to-earnings ratio of 80.34, a PEG ratio of 5.72 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $445.79.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the firm earned $1.00 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. On average, analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.